BristolMyers Squibb Company
Open
$56.85
Prev. Close
$56.85
High
$57.14
Low
$56.81
Market Snapshot
$116.34B
16.0
-4.42
$48.3B
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
Recently from Cashu
Bristol Myers Squibb Advances Oncology with Collaborations and Innovative Drug Developments
BristolMyers Squibb Company (Ticker: BMY) advances its position in oncology with strategic collaborations and innovative drug development. Recently, the company enters a clinical trial collaboration w…
Bristol-Myers Squibb's Opdivo Approval Enhances Frontline Cancer Treatment Options in Europe
Bristol-Myers Squibb Company (Ticker: BMY) achieves a significant milestone in cancer treatment with the European Commission's approval of Opdivo in combination with AVD as a frontline regimen for adv…
Bristol Myers Squibb Reports Success of Mezigdomide in Multiple Myeloma Phase 3 Trial
Bristol Myers Squibb Company (Ticker: BMY) has unveiled groundbreaking findings from its Phase 3 SUCCESSOR-2 trial, showcasing the efficacy of mezigdomide in patients with relapsed or refractory multi…
Bristol Myers Squibb Partners with Anthropic to Enhance Operations Using AI Technology
Bristol Myers Squibb Company (Ticker: BMY) partners with Anthropic to enhance its operational efficiency using advanced AI technology. This collaboration marks a significant milestone as it employs Cl…